WO2006028524A3 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase - Google Patents

Compositions and treatments for inhibiting kinase and/or hmg-coa reductase Download PDF

Info

Publication number
WO2006028524A3
WO2006028524A3 PCT/US2005/014843 US2005014843W WO2006028524A3 WO 2006028524 A3 WO2006028524 A3 WO 2006028524A3 US 2005014843 W US2005014843 W US 2005014843W WO 2006028524 A3 WO2006028524 A3 WO 2006028524A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmg
coa reductase
compositions
treatments
map kinase
Prior art date
Application number
PCT/US2005/014843
Other languages
French (fr)
Other versions
WO2006028524A2 (en
Inventor
John Griffin
William J Mydlowec
Guido Lanza
Jessen Yu
Original Assignee
Pharmix Corp
John Griffin
William J Mydlowec
Guido Lanza
Jessen Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmix Corp, John Griffin, William J Mydlowec, Guido Lanza, Jessen Yu filed Critical Pharmix Corp
Priority to JP2007511020A priority Critical patent/JP2007535558A/en
Priority to EP05818178A priority patent/EP1755607A2/en
Publication of WO2006028524A2 publication Critical patent/WO2006028524A2/en
Publication of WO2006028524A3 publication Critical patent/WO2006028524A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38a MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.
PCT/US2005/014843 2004-04-29 2005-04-29 Compositions and treatments for inhibiting kinase and/or hmg-coa reductase WO2006028524A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007511020A JP2007535558A (en) 2004-04-29 2005-04-29 Compositions and treatments for inhibiting kinases and / or HMG-COA reductase
EP05818178A EP1755607A2 (en) 2004-04-29 2005-04-29 Compositions and treatments for inhibiting kinase and/or hmg-coa reductase

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56711804P 2004-04-29 2004-04-29
US60/567,118 2004-04-29
US63068404P 2004-11-23 2004-11-23
US63068304P 2004-11-23 2004-11-23
US60/630,683 2004-11-23
US60/630,684 2004-11-23

Publications (2)

Publication Number Publication Date
WO2006028524A2 WO2006028524A2 (en) 2006-03-16
WO2006028524A3 true WO2006028524A3 (en) 2009-04-23

Family

ID=35451387

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/014833 WO2005115397A2 (en) 2004-04-29 2005-04-29 Compositions and treatments for modulating kinase and/or hmg-coa reductase
PCT/US2005/014843 WO2006028524A2 (en) 2004-04-29 2005-04-29 Compositions and treatments for inhibiting kinase and/or hmg-coa reductase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014833 WO2005115397A2 (en) 2004-04-29 2005-04-29 Compositions and treatments for modulating kinase and/or hmg-coa reductase

Country Status (3)

Country Link
EP (1) EP1755607A2 (en)
JP (1) JP2007535558A (en)
WO (2) WO2005115397A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329703B2 (en) 2005-02-15 2012-12-11 Xtl Biopharmaceuticals Ltd. Pyrazole compounds
US20090227602A1 (en) * 2005-10-28 2009-09-10 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
CA2680507A1 (en) 2006-10-13 2008-04-24 Xtl Biopharmaceuticals Ltd. Compounds and methods for treatment of hcv
WO2010038086A2 (en) 2008-10-02 2010-04-08 Respivert Limited Novel compounds
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
AU2009326148B2 (en) 2008-12-11 2014-05-08 Respivert Limited p38 MAP kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2308866A1 (en) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
DK3057969T3 (en) 2013-10-17 2018-09-24 Blueprint Medicines Corp COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
US10829493B2 (en) 2019-04-12 2020-11-10 Blueprint Medicines Corporation Compositions and methods for treating KIT- and PDGFRA-mediated diseases
CA3136707A1 (en) 2019-04-12 2020-10-15 Blueprint Medicines Corporation Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120848A (en) * 1988-10-03 1992-06-09 Glaxo Group Limited Imidazole derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177121B1 (en) * 1997-09-29 2001-01-23 Purdue Research Foundation Composition and method for producing low cholesterol eggs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120848A (en) * 1988-10-03 1992-06-09 Glaxo Group Limited Imidazole derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAN, C.: "Inhibitors of Cholesterol Biosynthesis. 1. 3,5-dihydroxy-7-(N-imidazolyl)-6- heptenoates and heptanoates, a novel series of HMG-CoA reductase inhibitors.", J. MED. CHEM., vol. 36, 1993, pages 3646 - 3657, XP002922110 *
SLISKOVIC, D.R.: "Inhibitors of Cholesterol Biosynthesis. 6. trans-6-[2-(2-N-hetroaryl-3,5- disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones.", J. MED. CHEM., vol. 35, 1992, pages 2095 - 2103, XP008122636 *

Also Published As

Publication number Publication date
WO2005115397A2 (en) 2005-12-08
EP1755607A2 (en) 2007-02-28
WO2005115397A3 (en) 2006-07-13
JP2007535558A (en) 2007-12-06
WO2006028524A2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
WO2007051065A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
WO2006028524A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
WO2007064797A3 (en) Inhibitors of c-met and uses thereof
WO2007079164A3 (en) Protein kinase inhibitors
WO2007067781A3 (en) 9-membered heterobicyclic compounds as inhibitors of protein kinases
WO2009006389A3 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2007011962A3 (en) Treatment of cancer
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2008083367A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2005123672A3 (en) Kinase inhibitors
WO2005107747A3 (en) Diindolymethane formulations for the treatment of leiomyomas
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
UA100007C2 (en) Heterocyclic inhibitors of mek, use thereof and pharmaceutical composition containing thereof
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2008030883A3 (en) Treatment of cancer
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
WO2008063213A3 (en) Uses and compositions for treatment of psoriatic arthritis
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
EP2476679A3 (en) Substituted triazoles useful as AXL inhibitors
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2007002744A3 (en) Aluminum phosphate based microspheres
WO2006091459A3 (en) Compositions and methods for treating vascular permeability

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005818178

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007511020

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 6868/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580019604.X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005818178

Country of ref document: EP